NCT01410890 - Pharmacokinetics of Alglucosidase Alfa in Patients With Pompe Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 3, 2014

Primary Completion Date

November 20, 2020

Study Completion Date

November 20, 2020

Conditions

Pompe DiseaseGlycogen Storage Disease Type II (GSD II)

Interventions

BIOLOGICAL

alglucosidase alfa

Intravenous (IV) infusion of 20mg/kg body weight every other week (qow)

Trial Locations (12)

Investigational Site Number 1028, Sofia

Investigational Site Number 840008, Valhalla

Investigational Site Number 840003, Fairfax

Investigational Site Number 840007, Cincinnati

Investigational Site Number 840005, Salt Lake City

Investigational Site Number 643001, Moscow

Investigational Site Number 643002, Moscow

Investigational Site Number 356002, Vellore

Investigational Site Number 356001, New Delhi

Investigational Site Number 804001, Kiev

Investigational Site Number 826003, Birmingham

Investigational Site Number 826002, Salford

All Listed Sponsors

lead

Genzyme, a Sanofi Company

INDUSTRY